World

Canada condemns China's steps against Canadian institutions over Uyghurs, Tibet

Dec 25, 2024

Ottawa [Canada], December 25: The Canadian government condemned China on Tuesday for taking steps against two Canadian institutions and 20 people involved in human rights issues concerning the Uyghurs and Tibet.
China announced the measures, which included asset freezes and bans on entry, on Sunday. Its targets included the Canada-based Uyghur Rights Advocacy Project and the Canada-Tibet Committee, China's foreign ministry said.
The Canadian statement urged China to respect its obligations under international law while also urging Canadians to exercise a high degree of caution in China due to the risk of arbitrary enforcement of local laws.
Rights groups accuse Beijing of widespread abuses of Uyghurs, a mainly Muslim ethnic minority that numbers around 10 million in the western region of Xinjiang, including the mass use of forced labour in camps. Beijing denies any abuses.
China seized control of Tibet in 1950 in what it describes as a "peaceful liberation" from feudalistic serfdom. International human rights groups and exiles, however, have routinely condemned what they call China's oppressive rule in Tibetan areas.
Source: Fijian Broadcasting Cooperation

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025